Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease [Yahoo! Finance]
Cognition Therapeutics, Inc. (CGTX)
Company Research
Source: Yahoo! Finance
developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode reviews how beta amyloid (Aß) oligomers cause synaptic dysfunction, which is correlated with cognitive decline. This conversation features a discussion of newly published research showing that Aß oligomers bind to synapses in brain tissue of Alzheimer's patients and how CT1812 acts to reverse their binding and reduce synaptotoxicity. Additionally, the panelists discuss using quantitative electroencephalography (EEG) as a real-time biomarker of synaptic function. In the Phase 2 ‘ SEQUEL' study of CT1812 in mild-to-moderate Alzheimer's disease, four weeks of treatment was associated with trends to improvement in synaptic function and brain connectivity. Finally, Dr. Hamby summarized results of proteomic analysis demonstrating the impact of CT1812 treatment on proteins and pathways alter
Show less
Read more
Impact Snapshot
Event Time:
CGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CGTX alerts
High impacting Cognition Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CGTX
News
- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $11.00 price target on the stock.MarketBeat
- Cognition Therapeutics, Inc. (NASDAQ: CGTX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.MarketBeat
- Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's DiseaseGlobeNewswire
- Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business UpdateGlobeNewswire
- Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies [Yahoo! Finance]Yahoo! Finance
CGTX
Earnings
- 5/7/24 - Miss
CGTX
Sec Filings
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- CGTX's page on the SEC website